Quote this publication Share Print

AVASTIN (bevacizumab), monoclonal antibody - OVARIAN CANCER

ONCOLOGY - Focus
Opinions on drugs - Posted on Oct 13 2016

Reason for request

Re-assessment of the actual benefit and the improvement in actual benefit

Minor improvement in the treatment of advanced stage ovarian cancer

  • AVASTIN has Marketing Authorisation in combination with carboplatin and paclitaxel in the first-line treatment of advanced stage epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
  • The addition of bevacizumab to carboplatin and to paclitaxel has demonstrated a modest effect on progression-free survival, without impacting the overall survival, but with an addition of adverse events such as bleeding, arterial hypertension and gastrointestinal perforations compared to carboplatin and paclitaxel.

Clinical Benefit

Substantial

-


Clinical Added Value

minor

-


Contact Us

Évaluation des médicaments